explore -WSS

explore

author：Wikipedia 2025-10-06 07:54:56 - browse：9

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Study: People of West African ancestry at greater risk of cardiac amyloidosis

entertainment

WSS

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Men with early prostate cancer can safely opt out of treatment

H5N1 bird flu: what we're starting to learn about infection in cows

Statins reduce cardiovascular risk in people living with HIV

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Sanofi strikes deal with Novavax, boosting the vaccine maker

focus

explore

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

First recipient of genetically engineered pig kidney has died

Drug repurposing or repositioning? The language matters

Medicare says breakthrough device reimbursement rule to come by summer

The high cost of giving birth even with insurance

Google says AlphaFold 3 can map a vast universe of biomolecules

Tori Bowie and the unacceptable rates of Black maternal death

Use wet bulb globe temperature, not heat index, to protect workers

Medicare proposal to cover medical devices draws a mixed reaction

After gene therapy, two congenitally deaf children hear for the first time

entertainment

Doctors have an ethical obligation to be advocates

Study: Adult vaccinations pay for themselves in societal benefits

Statins reduce cardiovascular risk in people living with HIV

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

How to protect coverage of PrEP

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

focus

entertainment

knowledge

entertainment